Bayer and CrossBay Medical Inc. announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer's leading hormonal IUS portfolio. The partnership will result in the further development and expansion of CrossBay's existing innovative CrossGlide?? technology.

The CrossGlide technology has the potential to substantially improve the intrauterine placement experience by limiting and reducing the discomfort some women may experience during IUS insertion. By removing these steps, the inserter also has the potential to reduce procedure time necessary for healthcare professionals. Pursing CrossBay's technology with Bayer's leading IUS portfolio will also result in adapting the manufacturing process and industrialization of the CrossGlide technology, building on Bayer's expertise in the field specifically at the company's production site in Turku, Finland.